Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Stuttgart - Delayed Quote EUR

Xencor Inc (XE9.SG)

Compare

12.20

-0.20

(-1.61%)

As of 7:22:15 PM GMT+1. Market Open.

Xencor Full Year 2024 Earnings: Beats Expectations

Xencor ( NASDAQ:XNCR ) Full Year 2024 Results Key Financial Results Revenue: US$110.5m (down 37% from FY 2023). Net...

Simply Wall St. 11 days ago

XNCR
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 25.30% and 293.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 12 days ago

XNCR
Xencor: Q4 Earnings Snapshot

PASADENA, Calif. AP) — Xencor Inc. XNCR) on Thursday reported a loss of $45.6 million in its fourth quarter.

Associated Press Finance 12 days ago

XNCR
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

PASADENA, Calif., February 27, 2025--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided clinical updates and priorities for 2025.

Business Wire 12 days ago

XNCR
Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Xencor (XNCR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks last month

XNCR
Xencor (NASDAQ:XNCR investor five-year losses grow to 50% as the stock sheds US$96m this past week

For many, the main point of investing is to generate higher returns than the overall market. But the main game is to...

Simply Wall St. last month

XNCR
Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround

Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks last month

XNCR
After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)

Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks last month

XNCR
Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks

The heavy selling pressure might have exhausted for Xencor (XNCR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks last month

XNCR
Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know

Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks last month

XNCR
All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy

Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 2 months ago

XNCR
Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 3 months ago

XNCR
Xencor to Participate at Upcoming Investor Conferences

PASADENA, Calif., November 26, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:

Business Wire 3 months ago

XNCR
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 3 months ago

XNCR
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Zacks 3 months ago

XNCR
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Market forces rained on the parade of Xencor, Inc. ( NASDAQ:XNCR ) shareholders today, when the analysts downgraded...

Simply Wall St. 3 months ago

XNCR
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 27.55% and 38.41%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

XNCR
Xencor: Q3 Earnings Snapshot

PASADENA, Calif. AP) — Xencor Inc. XNCR) on Wednesday reported a loss of $45.1 million in its third quarter.

Associated Press Finance 4 months ago

XNCR
Xencor Reports Third Quarter 2024 Financial Results

PASADENA, Calif., November 06, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third quarter ended September 30, 2024 and provided a review of recent business and clinical-stage program updates.

Business Wire 4 months ago

XNCR
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

PASADENA, Calif., November 04, 2024--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated dosing of healthy volunteers in the first-in-human study of XmAb®942, an investigational high-potency extended half-life anti-TL1A antibody. Xencor continues to expect initial data from the ongoing study during the first half of 2025.

Business Wire 4 months ago

XNCR

Performance Overview

Return	XE9.SG	S&P 500
YTD	-46.49%	-4.71%
1-Year	-44.04%	+9.50%
3-Year	-51.57%	+33.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Xencor Inc (XE9.SG)

Xencor Full Year 2024 Earnings: Beats Expectations

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Xencor: Q4 Earnings Snapshot

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Xencor (NASDAQ:XNCR investor five-year losses grow to 50% as the stock sheds US$96m this past week

Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround

After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)

Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks

Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know

All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy

Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet

Xencor to Participate at Upcoming Investor Conferences

Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade

Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

Xencor: Q3 Earnings Snapshot

Xencor Reports Third Quarter 2024 Financial Results

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Performance Overview